# Sermorelin Research: GHRH(1-29) Findings on Growth, Aging, and Cognition > Sermorelin research: GHRH(1-29) accelerated growth in deficient children and reversed age-related GH/IGF-1 declines in older men. A cited digest, with tesamorelin and ipamorelin kept distinct. The strongest, best-documented findings first — then the comparisons, then the honest gaps where adult anti-aging and body-composition claims outrun the direct evidence. ## Start here Sermorelin research has two firm anchors and a wide, softer frontier. The firm anchors: in growth-deficient children it sped up growth, and in older men it pushed an aged growth-hormone system back toward a younger range. The softer frontier is everything marketed to adults — fat loss, muscle, anti-aging — where the direct sermorelin evidence thins out and the best body-composition numbers actually come from a close relative, tesamorelin. This page leads with what is established, names the related-analog data as related-analog data, and leaves the empty spaces empty. IGF-1, mentioned throughout, is the liver-made growth signal that rises when growth hormone rises. ## What the research reports on sermorelin's effects The **sermorelin benefits** discussed in the literature are best read as measured outcomes, not promises. **Pediatric growth (the approved use).** In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, raising first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year — without excessive IGF-1 generation [2]. This is the clearest efficacy signal in the entire record, and it is the use sermorelin was approved for. **Reversing the aging GH/IGF-1 decline.** In healthy old men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose [3]. The aged axis responded to the upstream signal. **Cognition and IGF-1 (a related analog).** In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 with mild cognitive impairment — 20 weeks of a daily GHRH analog (tesamorelin, given before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [7]. Promising, but a single trial of a related analog — not a treatment claim for sermorelin itself. ## Reported side effects and safety considerations of sermorelin Reported adverse effects in the **sermorelin side effects** literature were generally mild, with injection-site reactions the most common; in the GHRH-analog cognition trial, adverse events were described as mild [7]. The aging study in older men reported no effect on fasting glucose at the doses used [3]. The principal theoretical concern is class-wide rather than sermorelin-specific. Growth hormone and IGF-1 are mitogenic — they drive cell growth — so chronically raising them is theorized to carry an oncologic consideration, even though sermorelin acts through the body's own feedback-regulated, pulsatile secretion rather than flooding the system. Long-term safety data specifically for adult, non-deficiency use remain limited [7]. Growth-hormone secretagogues, including GHRH analogs, are also prohibited in sport by WADA, and dedicated detection methods exist. None of this is medical advice; it is the safety frame the published record carries. ## Comparisons: sermorelin against its neighbors ### Sermorelin vs tesamorelin Sermorelin is native GHRH(1-29); tesamorelin is a stabilized GHRH analog with a longer duration and the body-composition track record sermorelin lacks. The clearest controlled body-composition and cognition data in this corpus come from tesamorelin — the 117% IGF-1 rise and 7.4% body-fat reduction in the cognition trial were tesamorelin results [7]. When this digest reports fat-loss numbers, they belong to tesamorelin unless explicitly stated otherwise; that line is held deliberately, because adult body-composition marketing tends to attach tesamorelin's data to sermorelin's name. ### Sermorelin vs ipamorelin: what is the difference? Sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor — a different mechanism entirely [4]. In adult female rats, the GHRPs ipamorelin and GHRP-6 increased bone mineral content, an effect attributed to that distinct secretagogue class [4]. The two reach more growth hormone by separate routes, and their non-GH effects do not transfer between classes. ## Efficacy, timeline, and the honest frontier ### Does sermorelin work? In its approved pediatric indication, once-daily subcutaneous GHRH(1-29) accelerated growth in deficient children (height velocity ~4.1 to ~7-8 cm/year) [2], and in older men 14 days of dosing reversed age-related GH and IGF-1 declines [3]. Adult anti-aging efficacy is far less established — an editorial called secretagogue anti-aging use "not yet ready for prime time" [14]. ### How long does it take for sermorelin to work? Acute growth-hormone release follows a single dose within hours — GH stayed elevated for about 3 hours after an intravenous dose [13] — while the aging study measured GH/IGF-1 changes over 14 days [3] and the pediatric growth endpoint was assessed over the first year [2]. These are study endpoints, not personal expectations. ### Does sermorelin burn fat? Is it effective for weight loss? No sermorelin study establishes it as a fat-loss or weight-loss treatment. The closest controlled body-composition data come from the related analog tesamorelin and from the GHRH cognition trial that reported a 7.4% reduction in percent body fat [7]. Anti-aging and body-composition marketing outpaces the direct sermorelin evidence, and a comprehensive 2025 review of GHRH and its analogues frames the therapeutic landscape with the same caution [15]. ### Will sermorelin raise my IGF-1 levels? In healthy older men, GHRH(1-29) twice daily for 14 days produced dose-related increases in GH and IGF-1, with high-dose values no longer differing from young men [3]; a related GHRH analog raised IGF-1 by 117% within the physiologic range [7]. Reported as study outcomes, not a personal prediction. ### Does sermorelin build muscle? The corpus contains no controlled sermorelin muscle-hypertrophy trial. GH/IGF-1-axis modulation has been discussed in reviews as a candidate strategy against age-related muscle loss, but that is framing, not proof [15]. ### Sermorelin before and after: what changes do studies report? Measured before/after changes in the literature include accelerated height velocity in deficient children (~4.1 to ~7-8 cm/year) [2], reversal of age-related GH/IGF-1 declines in older men [3], and — for the related GHRH analog — a 117% IGF-1 increase with a 7.4% body-fat reduction [7]. These are trial outcomes, not personal results. ### What is sermorelin used for? Historically it was an FDA-approved prescription product (NDA 020443) used to evaluate and treat growth-hormone deficiency and short stature in children, and it was also used diagnostically as a GHRH stimulation agent. Adult GH-axis research has examined aging, body composition, sleep, and cognition; those non-pediatric uses are research contexts, not approved indications. ### Does sermorelin affect the brain? GHRH administration has measurable neuroendocrine effects: a GHRH analog had a favorable effect on cognition in older adults [7], and GHRH influences slow-wave sleep, the stage tied to nocturnal GH. These are research observations in study populations. ### Can sermorelin or GHRH improve cognition in older adults? In a randomized, double-blind, placebo-controlled trial of 152 older adults (including 66 with mild cognitive impairment), 20 weeks of a daily GHRH analog had a favorable effect on cognition (P=0.03; executive function P=0.005), alongside a 117% IGF-1 rise and a 7.4% body-fat reduction [7]. Promising, but a single trial of a related analog — not a treatment claim for sermorelin. --- A night research board of the sermorelin literature — slow-wave sleep, the nocturnal growth-hormone pulse, and the GHRH(1-29) findings pinned and cited, with the body-composition data taped where it belongs as tesamorelin and the empty adult-safety clipping left torn open; no clinic behind the board and nothing here dosed, dispensed, or sold.